KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA’s interim CEO since February 2025 and previously served as KALA’s President and Chief Operating Officer (COO).

Read more at globenewswire.com